1)Rahib L, et al:Projecting cancer incidence and deaths to 2030;The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913-2921, 2014
2)Egawa S, et al:Japan pancreatic cancer registry;30th year anniversary;Japan Pancreas Society. Pancreas 41:985-992, 2012
3)日本膵癌学会膵癌診療ガイドライン改訂委員会(編):膵癌診療ガイドライン2019年版.金原出版,2019
4)Sharma C, et al:Advances in diagnosis, treatment and palliation of pancreatic carcinoma;1990-2010. World J Gastroenterol 17:867-897, 2011
5)日本膵臓学会膵癌登録委員会:膵癌登録報告.膵臓22:el-427, 2007
6)江川新一,他:小膵癌の全国集計の解析.膵臓19:558-566, 2004
7)清水京子,白鳥敬子:家族歴,既往歴を中心とした膵癌の危険因子の検討.消化器内科55:70-73, 2012
8)Matsubayashi H, et al:Risk factors of familial pancreatic cancer in Japan;Current smoking and recent onset of diabetes. Pancreas 40:974-978, 2011
9)Klein AP, et al:Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634-2638, 2004
10)Kitano M, et al:Needle tract seeding after endoscopic ultrasound-guided tissue acquisition of pancreatic tumors;Nationwide survey in Japan. DEN 03, 2022 https://doi.org/10.1111/den.14346(2022年8月閲覧)
11)日本膵臓学会(編):膵癌取り扱い規約 第7版増補版.金原出版,2020
12)Unno M, et al:Randomized phase Ⅱ/Ⅲ trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer(Prep-02/JSAP-05). J Clin Oncol 37(suppl):89, 2019
13)Conroy T, et al:FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Eng J Med 64:1817-1825, 2011.
14)Van Hoff DD, et al:Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Eng J Med 369:1691-1703, 2013
15)Sohal DPS, et al:Metastatic pancreatic cancer;ASCO clinical practice guideline update. J Clin Oncol 36:2545-2556, 2018